Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11749876 | 0.91 | CES1 (0.53) | HTR2CCYP2A6MAOAMAOBACHE | |
| SCHEMBL29565246 | 0.91 | CES1 (0.53) | HTR2CCYP2A6MAOAMAOBACHE | |
| SCHEMBL30542795 | 0.90 | HTR2C (0.50) | HTR2CCYP2A6MAOAMAOBACHE | |
| SCHEMBL15522534 | 0.82 | HTR2C (0.67) | HTR2CHTR2B | |
| SCHEMBL10153320 | 0.79 | HTR2C (0.67) | HTR2CMAOAMAOBACHECES1 | |
| SCHEMBL6202369 | 0.78 | HTR2C (0.53) | HTR2CACHECA12CA9HTR2B | |
| SCHEMBL11502277 | 0.77 | CES1 (0.49) | CYP2A6MAOAMAOBCES1CA12 | |
| SCHEMBL30542701 | 0.75 | NOTUM (0.37) | CYP2A6MAOAMAOBKDM4EMAPT | |
| SCHEMBL29876743 | 0.73 | HTR2C (0.51) | HTR2CCYP2A6ACHECES1CA12 | |
| SCHEMBL4502507 | 0.73 | ACHE (0.60) | HTR2CMAOAMAOBACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020147848-A1 | TRICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-07-23 | — | — | WO | disclosed |
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | GLAXO GROUP LIMITED (GB) | 2007-12-20 | — | — | US | disclosed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
| EP-1483265-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076442-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | HTR2C 2553/4885CYP2A6 2565/4885MAOA 3011/4885 |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | IL17A, CYP51A1, IL15 | HTR2C 3188/4885CYP2A6 260/4885MAOA 2881/4885 |
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | HTR2C 2553/4885CYP2A6 2565/4885MAOA 3011/4885 |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | HTR2C 2553/4885CYP2A6 2565/4885MAOA 3011/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | HTR2C 2553/4885CYP2A6 2565/4885MAOA 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.